title: Genetic variations in EGF and EGFR and glioblastoma outcome.
abstract: Few prognostic factors have been associated with glioblastoma survival. We analyzed a complete tagging of the epidermal growth factor (EGF) and EGF receptor (EGFR) gene polymorphisms as potential prognostic factors. Thirty tagging single-nucleotide polymorphisms (SNPs) in EGF and 89 tagging SNPs in EGFR were analyzed for association with survival in 176 glioblastoma cases. Validation analyses were performed for 4 SNPs in a set of 638 glioblastoma patients recruited at The University of Texas M. D. Anderson Cancer Center (MDACC). Three hundred and seventy-four glioblastoma patients aged 50 years or older at diagnosis were subanalyzed to enrich for de novo arising glioblastoma. We found 7 SNPs in haplotype 4 in EGF that were associated with prognosis in glioblastoma patients. In EGFR, 4 of 89 SNPs were significantly associated with prognosis but judged as false positives. Four of the significantly associated EGF polymorphisms in haplotype block 4 were validated in a set from MDACC; however, none of the associations were clearly replicated. rs379644 had a hazard ratio (HR) of 1.19 (0.94-1.51) in the whole population with 18.6 months survival in the risk genotype compared with 24.5 in the reference category. As the median age differed slightly between the 2 study sets, the MDACC cases aged 50 or older at diagnosis were analyzed separately (rs379644, HR 1.32 [0.99-1.78]), which is marginally significant and partially validates our findings. This study is, to our knowledge, the first to perform a comprehensive tagging of the EGF and EGFR genes, and the data give some support that EGF polymorphisms might be associated with poor prognosis. Further confirmation in independent data sets of prospective studies is necessary to establish EGF as prognostic risk factor.
authors.affiliation: Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden.
authors.forename: Sara
authors.initials: S
authors.lastname: Sjöström
authors.forename: Ulrika
authors.initials: U
authors.lastname: Andersson
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Liu
authors.forename: Thomas
authors.initials: T
authors.lastname: Brännström
authors.forename: Helle
authors.initials: H
authors.lastname: Broholm
authors.forename: Christoffer
authors.initials: C
authors.lastname: Johansen
authors.forename: Helle
authors.initials: H
authors.lastname: Collatz-Laier
authors.forename: Roger
authors.initials: R
authors.lastname: Henriksson
authors.forename: Melissa
authors.initials: M
authors.lastname: Bondy
authors.forename: Beatrice
authors.initials: B
authors.lastname: Melin
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality; D004815:Epidermal Growth Factor / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005838:Genotype; D005909:Glioblastoma / Q000235:genetics* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012307:Risk Factors; D055815:Young Adult
chemical_list: D004815:Epidermal Growth Factor; D066246:ErbB Receptors